{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-151979","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.518693+00:00","generated_at":"2026-05-15T06:35:11.056505+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Palvella Therapeutics appoints John Doux, M.D. to Board of Directors","bullets":["Board increased to 7 members; Dr. Doux appointed as Class III director with term expiring at 2026 Annual Meeting.","Dr. Doux is a board-certified dermatologist and analyst at Palo Alto Investors LP since 2004.","Granted option to purchase 6,000 shares vesting in equal monthly installments over 36 months.","Previously served on Palvella's board before reverse merger (2019-2022).","Board determined Dr. Doux independent under Nasdaq listing rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-151979","json":"https://secwatch.observer/filing/0001193125-26-151979.json","markdown":"https://secwatch.observer/filing/0001193125-26-151979.md","text":"https://secwatch.observer/filing/0001193125-26-151979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526151979/0001193125-26-151979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526151979/pvla-20260413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:35:11.056505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}